Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a Healthcare company (Biotechnology) with a market capitalization of $3.5B. The Maz Rating grades it against the other companies in its sector.
Amylyx Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $27.52, Amylyx Pharmaceuticals, Inc. trades at 4.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -41.5%, return on invested capital of -23.2% and a free cash flow yield of -3.7%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 26.81. Over the past 52 weeks the share price ranged from $10.83 to $41.14, with a beta of -0.20.
Amylyx Pharmaceuticals, Inc. does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 10 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.